Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.

Avery LB, Wang M, Kavosi MS, Joyce A, Kurz JC, Fan YY, Dowty ME, Zhang M, Zhang Y, Cheng A, Hua F, Jones HM, Neubert H, Polzer RJ, O'Hara DM.

MAbs. 2016 Aug-Sep;8(6):1064-78. doi: 10.1080/19420862.2016.1193660. Epub 2016 May 27.

2.

The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery.

Lin J, Sahakian DC, de Morais SM, Xu JJ, Polzer RJ, Winter SM.

Curr Top Med Chem. 2003;3(10):1125-54. Review.

PMID:
12769713
3.

Efficacy of trovafloxacin for treatment of experimental Bacteroides infection in young and senescent mice.

Thadepalli H, Chuah SK, Reddy U, Hanna N, Clark R, Polzer RJ, Gollapudi S.

Antimicrob Agents Chemother. 1997 Sep;41(9):1933-6.

4.

Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin.

Vincent J, Venitz J, Teng R, Baris BA, Willavize SA, Polzer RJ, Friedman HL.

J Antimicrob Chemother. 1997 Jun;39 Suppl B:75-80.

PMID:
9222074
5.

A study of the phototoxic potential of trovafloxacin in BALB/c mice.

Mayne JT, Johnson NJ, Kluwe WM, Lencoski DL, Polzer RJ.

J Antimicrob Chemother. 1997 Jun;39 Suppl B:67-73.

PMID:
9222073
6.

Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis.

Khan AA, Slifer T, Araujo FG, Polzer RJ, Remington JS.

Antimicrob Agents Chemother. 1997 May;41(5):893-7.

7.

In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.

Thadepalli H, Reddy U, Chuah SK, Thadepalli F, Malilay C, Polzer RJ, Hanna N, Esfandiari A, Brown P, Gollapudi S.

Antimicrob Agents Chemother. 1997 Mar;41(3):583-6.

8.

Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.

Gootz TD, Zaniewski R, Haskell S, Schmieder B, Tankovic J, Girard D, Courvalin P, Polzer RJ.

Antimicrob Agents Chemother. 1996 Dec;40(12):2691-7.

9.

Inhibition of benzo[a]pyrene metabolism by insulin, FITC-insulin and an FITC-insulin-antibody conjugate in the human hepatoma cell line HepG2.

Polzer RJ, Coffing SL, Marcus CB, Park SS, Gelboin HV, Baird WM.

Chem Biol Interact. 1995 Aug 18;97(3):307-18.

PMID:
7671346

Supplemental Content

Loading ...
Support Center